A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Recruiting · Phase 3 · NCT06100744
Conditions: Juvenile Psoriatic Arthritis
At a glance
- Research payments reported, 2025
- $195,326
- U.S. investigators named
- 10
- Sites paid
- 10
- Planned or actual enrollment
- 40
About the trial
- Sponsor
- AbbVie
- Tested
- Adalimumab (drug), Risankizumab (drug)
- Dates
- Started 2024-07-08; completion 2028-10
- Results posted
- Not yet
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. PsA that begins before a patient's 16th birthday is called juvenile PsA (jPsA).This study will evaluate how safe risankizumab is for the treatment of psoriatic arthritis and to assess change in disease symptoms. Risankizumab is being studied for the treatment of jPsA and adalimumab is approved for the treatment of jPsA. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participan…
From ClinicalTrials.gov, last updated 2026-09-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $195,326 in research payments for this study in 2025 (39 payments).
Products named: Skyrizi
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Lina Al-jaberi, MD Pediatrics · Little Rock, AR
- Sangeeta Sule, M.D. Pediatrics · Washington, DC
- Kristina M. Wiers-shamir, M.D. Pediatrics · Boca Raton, FL
- Stacey E. Tarvin, M.D. Pediatrics · Indianapolis, IN
- Bryce A. Binstadt, M.D., PH.D. Pediatrics · Minneapolis, MN
- Eveline Y. Wu, MD Allergy & Immunology · Chapel Hill, NC
- Christine Hom, MD Pediatrics · Valhalla, NY
- Hulya Bukulmez, MD Pediatrics · Cleveland, OH
- Ruy Carrasco, MD Pediatrics · Austin, TX
- Aimee O. Hersh, M.D. Pediatrics · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Metrohealth System, OH $58,699
- Child Neurology Consultants $53,612
- Regents of the Univ of Minnesota $16,080
- Indiana University $13,178
- Arkansas Childrens Research $13,072
- Childrens Research Institute $12,613
- University of Utah Hospital and Clinics, UT $9,282
- New York Medical College $6,840
- Memorial Regional Hospital, FL $6,543
- University of North Carolina $5,408
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.